New lupus endpoint key to Phase III success for AZ’s anifrolumab

AstraZeneca's positive data for anifrolumab is the first successful Phase III trial in lupus in about a decade. But a previous Phase III failure for the mAb on a different endpoint leaves the pharma unable to commit to a timeline for regulatory submission just yet.

On Thursday, AstraZeneca

Read the full 474 word article

How to gain access

Continue reading with a
two-week free trial.